Biotech

The global peptide CDMO market hits $9B by 2036. How Bachem, PolyPeptide, and Lonza can build direct pipeline beyond GLP-1 anchor contracts.

The oligonucleotide market hits USD 5.42B in 2026 at 13.14% CAGR. How Swiss CDMOs like Bachem and Microsynth win therapeutic-grade contracts.

Swiss biologics CDMOs anchor a CHF 57.4B immunological export engine. How Lonza, Celonic and specialty players win clients beyond CPHI.

Swiss antibody-drug conjugate CDMOs sit on a market projected to hit $15.4B in 2026. Here is how Cerbios, Lonza, ADC Therapeutics and Araris compete.

France exported $9.53B of vaccines and biologicals in 2024. How French vaccine manufacturers reach global procurement buyers in 2026.

France is set to launch 44 new cell and gene therapies by 2030. How French CDMOs win ATMP, CAR-T, and viral vector mandates from global sponsors.

Sanofi committed over EUR 2.5B to French biologics. How GTP Bioways, Cenexi and peers win mAb and biosimilar contracts beyond CPHI.